High-level production (880 mg liter؊1 ) and isolation of the anteiso-C 17 isoform of the lipopeptide mycosubtilin produced by a genetically engineered Bacillus subtilis strain are reported. Antifungal activity of this isoform, as determined via culture and fluorometric and cell leakage assays, suggests its potential therapeutic use as an antifungal agent, in particular against Candida spp.The soil bacterium Bacillus subtilis ATCC 6633 synthesizes the lipopeptides mycosubtilin and surfactin via a so-called nonribosomal peptide synthetase. Mycosubtilin belongs to the iturin family and is composed of seven ␣-amino acids linked to a unique C 16 or C 17 -amino fatty acid with a linear or branched (iso or anteiso) acyl chain (15). This amphiphilic structure confers interesting biological properties on this secondary metabolite, particularly antifungal activity, which increases with the number of carbon atoms of the acyl chain (10). However, studies and applications of mycosubtilin are compromised by limited production by the native producer, cosynthesis of surfactin, and the existence of different mycosubtilin homologues and isoforms. In this work, utilization of specific precursors together with appropriate culture conditions for a genetically engineered strain led to the synthesis of a large amount of the most biologically active mycosubtilin homologue. Structural characterizations by mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy demonstrated that this homologue corresponds to the anteiso-C 17 isoform. Its antifungal activity against pathogenic Candida spp. was examined by MIC determination, fluorescence spectroscopy, and leakage experiments.Overproduction of mycosubtilin in B. subtilis ATCC 6633 was obtained by replacement of the native promoter of the myc operon, which encodes mycosubtilin synthetase, by the strong and tightly regulated xylA promoter from the Bacillus megaterium xylose isomerase (16). To this end, a repressor-promoter xylR-pxylA fragment was PCR amplified from pAXO1 (9) with Pfu DNA polymerase (Promega) and primers R100 and R101 before being cloned at the HincII site of pBG103 to yield pBG113 (Tables 1 and 2). Then, a spectinomycin resistance cassette was rescued from pRFB122 by PstI/EagI digestion and inserted into pBG113 at the corresponding site to yield pBG113s (Table 1). This construct was used to transform B. subtilis ATCC 6633 as previously described (8), and transformants were selected on Luria-Bertani plates supplemented with spectinomycin (100 g/ml). Correct integration in the resulting RFB107 strain was verified by analytical PCR using primers R102 and R103 (Table 2). In a second step, the srf operon, encoding surfactin synthetase, was disrupted in RFB107 to render the strain unable to synthesize surfactin. The knockout was targeted downstream of the comS regulator involved in competence mechanisms, which lies nested and out of frame within the srf operon (6, 7). The disruption cassette was obtained by a ligation-mediated PCR method (12) as follows. Fragments of s...